文献速递细菌感染、耐药与抗菌药物医院感染防控

欧洲六种关键病原体耐药血流感染超额健康风险的系统综述

A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe.
PubMed 文献 · Clin Microbiol Infect · 2023-10-04

该系统综述与Meta分析检索1990年1月至2022年5月MEDLINE、Embase及灰色文献,纳入56项耐药血流感染研究,采用随机效应模型合并病原体特异性负担估计。耐药血流感染较敏感血流感染的全因死亡粗估计OR从碳青霉烯耐药铜绿假单胞菌1.31至碳青霉烯耐药肺炎克雷伯菌3.44不等。

要点

  • 耐药血流感染较敏感血流感染全因死亡粗估计OR为1.31(碳青霉烯耐药铜绿假单胞菌)至3.44(碳青霉烯耐药肺炎克雷伯菌)。
  • 与未感染患者比较,耐万古霉素肠球菌和MRSA血流感染死亡OR分别为11.19和6.18。
  • 56项研究中46项(82.1%)比较耐药与敏感血流感染,55项(98.6%)报告死亡率。

核心结论

  • 耐药血流感染与死亡率增加相关,效应大小受病原体类型和比较对象影响。
  • 未来研究应解决病原体和感染特异性负担的关键知识缺口,以指导新型干预措施的开发。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase和灰色文献,时间范围为1990年1月至2022年5月。
  • 纳入报告六种关键耐药病原体负担数据的研究:碳青霉烯耐药铜绿假单胞菌和鲍曼不动杆菌、第三代头孢菌素或碳青霉烯耐药大肠埃希菌和肺炎克雷伯菌、耐甲氧西林金黄色葡萄球菌(MRSA)和耐万古霉素屎肠球菌。
  • 对MRSA及第三代头孢菌素耐药大肠埃希菌和肺炎克雷伯菌血流感染,鉴定到五项或以上欧洲研究;对其他病原体,检索扩展至高收入国家。
  • 研究对象为诊断为耐药血流感染的儿童和成人患者。
  • 偏倚风险评估采用改编版Joanna-Briggs研究所评估工具。

主要发现

  • 筛选7154条标题、1078篇全文,最终发现56项血流感染研究。
  • 多数研究比较耐药与敏感血流感染结局(46/56,82.1%),并报告死亡率(55/56,98.6%)。
  • 耐药与敏感血流感染全因死亡粗估计OR从碳青霉烯耐药铜绿假单胞菌1.31(95%CI 1.03-1.68)至碳青霉烯耐药肺炎克雷伯菌3.44(95%CI 1.62-7.32)。
  • 与未感染患者比较的死亡粗估计仅耐万古霉素肠球菌和MRSA血流感染可获取,OR分别为11.19(95%CI 6.92-18.09)和6.18(95%CI 2.10-18.17)。

关键数值与推荐

  • 耐药与敏感血流感染全因死亡粗估计OR:碳青霉烯耐药铜绿假单胞菌1.31(95%CI 1.03-1.68)。
  • 耐药与敏感血流感染全因死亡粗估计OR:碳青霉烯耐药肺炎克雷伯菌3.44(95%CI 1.62-7.32)。
  • 与未感染患者比较死亡粗估计OR:耐万古霉素肠球菌11.19(95%CI 6.92-18.09)。
  • 与未感染患者比较死亡粗估计OR:MRSA 6.18(95%CI 2.10-18.17)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance is a global threat, which requires novel intervention strategies, for which priority pathogens and settings need to be determined. OBJECTIVES: We evaluated pathogen-specific excess health burden of drug-resistant bloodstream infections (BSIs) in Europe. METHODS: A systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, and grey literature for the period January 1990 to May 2022. STUDY ELIGIBILITY CRITERIA: Studies that reported burden data for six key drug-resistant pathogens: carbapenem-resistant (CR) Pseudomonas aeruginosa and Acinetobacter baumannii, third-generation cephalosporin or CR Escherichia coli and Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium. Excess health outcomes compared with drug-susceptible BSIs or uninfected patients. For MRSA and third-generation cephalosporin E. coli and K. pneumoniae BSIs, five or more European studies were identified. For all others, the search was extended to high-income countries. PARTICIPANTS: Paediatric and adult patients diagnosed with drug-resistant BSI. INTERVENTIONS: Not applicable. ASSESSMENT OF RISK OF BIAS: An adapted version of the Joanna-Briggs Institute assessment tool. METHODS OF DATA SYNTHESIS: Random-effect models were used to pool pathogen-specific burden estimates. RESULTS: We screened 7154 titles, 1078 full-texts and found 56 studies on BSIs. Most studies compared outcomes of drug-resistant to drug-susceptible BSIs (46/56, 82.1%), and reported mortality (55/56 studies, 98.6%). The pooled crude estimate for excess all-cause mortality of drug-resistant versus drug-susceptible BSIs ranged from OR 1.31 (95% CI 1.03-1.68) for CR P. aeruginosa to OR 3.44 (95% CI 1.62-7.32) for CR K. pneumoniae. Pooled crude estimates comparing mortality to uninfected patients were available for vancomycin-resistant Enterococcus and MRSA BSIs (OR of 11.19 [95% CI 6.92-18.09] and OR 6.18 [95% CI 2.10-18.17], respectively). CONCLUSIONS: Drug-resistant BSIs are associated with increased mortality, with the magnitude of the effect influenced by pathogen type and comparator. Future research should address crucial knowledge gaps in pathogen- and infection-specific burdens to guide development of novel interventions.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Hassoun-Kheir N, Guedes M, Ngo Nsoga MT, et al. A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe. Clin Microbiol Infect. 2023. PMID: 37802750. doi:10.1016/j.cmi.2023.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。